Exhibit 99.1 Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif. – May 6, 2026 – Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalt ...